Evaluation of serum HER-2/neu extracelluar domain in breast cancer patients: Correlation with tissue HEr-2/neu status and clinicopathological factors

Journal of the Korean Surgical Society

Volumn 78, Issue 5, 2010, Pages 271-276

  Kang, Sun Hee ^a   Cho, Jihyoung ^a   Ha, Jung Sook ^a   Kwon, Sun Young ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

Breast cancer; Fluorescence in situ hybridization; Immunohistochemistry; Serum HER2 ECD

Indexed keywords

EID: 79960164317     PISSN: 12260053     EISSN: 20930488     Source Type: Journal    
DOI: 10.4174/jkss.2010.78.5.271     Document Type: Article

References (20)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
3. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36. (Pubitemid 46039831)
4. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
5. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991; 266:1716-20. (Pubitemid 21908361)
6. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999;59:1196-201. (Pubitemid 29136246)
7. Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT, et al. C-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation. Tumori 2006;92:311-7. (Pubitemid 44525308)
8. Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 2008;19:883-90. (Pubitemid 351627302)
9. Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009;27:1685-93.
10. Muller V, Witzel I, Luck HJ, Kohler G, von Minckwitz G, Mobus V, et al. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 2004;86:9-18. (Pubitemid 38918894)
11. Colomer R, Llombart-Cussac A, Lloveras B, Ramos M, Mayordomo JI, Fernandez R, et al. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. Cancer 2007;110:2178-85. (Pubitemid 350100738)
12. Lee JS, Min WK, Park EH, Lim WS, Choi SL, Son BH, et al. Correlation between the Her-2/neu status as determined by immunohistochemical analysis and the serum Her-2/neu concentration as determined by the use of ADVIA Cencaur. automated immunoassay in breast cancer patients. J Breast Cancer 2008;11:116-24.
13. Kim JW, Kim SY, Lee HS, Woo HD, Son DM, Lim CW, et al. Establishment for reference range of serum HER-2/neu in Korean healthy women. J Breast Cancer 2006;9:301-8.
14. Kong SY, Kang JH, Kwon Y, Kang HS, Chung KW, Kang SH, et al. Serum HER-2 concentration in patients with primary breast cancer. J Clin Pathol 2006;59:373-6.
15. Kong SY, Nam BH, Lee KS, Kwon Y, Lee ES, Seong MW, et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem 2006; 52:1510-5. (Pubitemid 44148313)
16. Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005;16:234-9. (Pubitemid 40309302)
17. Harris L, Luftner D, Jager W, Robertson JF. C-erbB-2 in serum of patients with breast cancer. Int J Biol Markers 1999;14:8-15. (Pubitemid 29237570)
18. Garoufali A, Kyriakou F, Kountourakis P, Yioti I, Malliou S, Nikaki A, et al. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. J BUON 2008;13:409-13.
19. Narita T, Funahashi H, Satoh Y, Takagi H. C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 1992;24:97-102. (Pubitemid 23063892)
20. Willsher PC, Beaver J, Pinder S, Bell JA, Ellis IO, Blamey RW, et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996;40: 251-5. (Pubitemid 26336120)